Loading cancer entity…
Loading cancer entity…
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07813351 | PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours(PRESTO) | not yet recruiting | Phase 3 | 82 | University College, LondonOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT02288962 | Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas | active not recruiting | Phase 3 | 60 | St. Olavs HospitalOTHER | 2 | Jul 21, 2026 |
| clinicaltrials |
| NCT07463235 | Safety and Potency of a High Cabergoline Dosage in Microprolactinomas(SPARAGMOS) | recruiting | Phase 3 | 70 | University of Sao Paulo General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02419664 | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | terminated | Phase 3 | 22 | Göteborg UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04244708 | The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas | unknown | Phase 2 / Phase 3 | 150 | Peking Union Medical College HospitalOTHER | 0 | Jan 28, 2020 | clinicaltrials |
| NCT03271918 | Cabergoline in Nonfunctioning Pituitary Adenomas | completed | Phase 3 | 140 | University of Sao Paulo General HospitalOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials